Galapagos (NASDAQ:GLPG) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Wednesday.
Other equities analysts have also recently issued research reports about the company. BTIG Research reiterated a “buy” rating and issued a $118.00 price target on shares of Galapagos in a report on Monday, November 20th. Stifel Nicolaus reiterated a “buy” rating and issued a $120.00 price target on shares of Galapagos in a report on Sunday, October 29th. Zacks Investment Research upgraded Galapagos from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. Morgan Stanley reiterated an “overweight” rating and issued a $123.00 price target (up previously from $92.00) on shares of Galapagos in a report on Friday, October 6th. Finally, ValuEngine cut Galapagos from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $111.00.
Shares of Galapagos (GLPG) traded down $0.17 during trading hours on Wednesday, hitting $118.22. The stock had a trading volume of 92,942 shares, compared to its average volume of 102,408. Galapagos has a 52 week low of $63.69 and a 52 week high of $121.09. The firm has a market capitalization of $6,030.00, a price-to-earnings ratio of -128.50 and a beta of 0.75.
TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/31/galapagos-glpg-upgraded-by-bidaskclub-to-buy.html.
Galapagos Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.